Prescription drug monitoring programs operational characteristics and fatal heroin poisoning

Silvia S. Martins, William Ponicki, Nathan Smith, Ariadne Rivera-Aguirre, Corey S. Davis, David S. Fink, Alvaro Castillo-Carniglia, Stephen G. Henry, Brandon D.L. Marshall, Paul Gruenewald, Magdalena Cerdá

Research output: Contribution to journalArticle

Abstract

Background: Prescription drug monitoring programs (PDMP), by reducing access to prescribed opioids (POs), may contribute to a policy environment in which some people with opioid dependence are at increased risk for transitioning from POs to heroin/other illegal opioids. This study examines how PDMP adoption and changes in the characteristics of PDMPs over time contribute to changes in fatal heroin poisoning in counties within states from 2002 to 2016. Methods: Latent transition analysis to classify PDMPs into latent classes (Cooperative, Proactive, and Weak) for each state and year, across three intervals (1999–2004, 2005–2009, 2010–2016). We examined the association between probability of PDMP latent class membership and the rate of county-level heroin poisoning death. Results: After adjustment for potential county-level confounders and co-occurring policy changes, adoption of a PDMP was significantly associated with increased heroin poisoning rates (22% increase by third year post-adoption). Findings varied by PDMP type. From 2010–2016, states with Cooperative PDMPs (those more likely to share data with other states, to require more frequent reporting, and include more drug schedules) had 19% higher heroin poisoning rates than states with Weak PDMPs (adjusted rate ratio [ARR] = 1.19; 95% CI = 1.14, 1.25). States with Proactive PDMPs (those more likely to report outlying prescribing and dispensing and provide broader access to law enforcement) had 6% lower heroin poisoning rates than states with No/Weak PDMPs (ARR = 0.94; 95% CI = 0.90, 0.98). Conclusion: There is a consistent, positive association between state PDMP adoption and heroin poisoning mortality. However, this varies by PDMP type, with Proactive PDMPs associated with a small reduction in heroin poisoning deaths. This raises questions about the potential for PDMPs to support efforts to decrease heroin overdose risk, particularly by using proactive alerts to identify patients in need of treatment for opioid use disorder. Future research on mechanisms explaining the reduction in heroin poisonings after enactment of Proactive PDMPs is merited.

Original languageEnglish (US)
Pages (from-to)174-180
Number of pages7
JournalInternational Journal of Drug Policy
Volume74
DOIs
StatePublished - Dec 2019

Fingerprint

Prescription Drugs
Drug Monitoring
Heroin
Poisoning
Opioid Analgesics
RV 538
Law Enforcement
Appointments and Schedules

Keywords

  • Fatal heroin poisonings
  • Latent classes
  • Overdose
  • Prescription drug monitoring programs

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Policy

Cite this

Prescription drug monitoring programs operational characteristics and fatal heroin poisoning. / Martins, Silvia S.; Ponicki, William; Smith, Nathan; Rivera-Aguirre, Ariadne; Davis, Corey S.; Fink, David S.; Castillo-Carniglia, Alvaro; Henry, Stephen G.; Marshall, Brandon D.L.; Gruenewald, Paul; Cerdá, Magdalena.

In: International Journal of Drug Policy, Vol. 74, 12.2019, p. 174-180.

Research output: Contribution to journalArticle

Martins, SS, Ponicki, W, Smith, N, Rivera-Aguirre, A, Davis, CS, Fink, DS, Castillo-Carniglia, A, Henry, SG, Marshall, BDL, Gruenewald, P & Cerdá, M 2019, 'Prescription drug monitoring programs operational characteristics and fatal heroin poisoning', International Journal of Drug Policy, vol. 74, pp. 174-180. https://doi.org/10.1016/j.drugpo.2019.10.001
Martins, Silvia S. ; Ponicki, William ; Smith, Nathan ; Rivera-Aguirre, Ariadne ; Davis, Corey S. ; Fink, David S. ; Castillo-Carniglia, Alvaro ; Henry, Stephen G. ; Marshall, Brandon D.L. ; Gruenewald, Paul ; Cerdá, Magdalena. / Prescription drug monitoring programs operational characteristics and fatal heroin poisoning. In: International Journal of Drug Policy. 2019 ; Vol. 74. pp. 174-180.
@article{1c4fb1cdf2d24c8085e123fc0b8fd6f0,
title = "Prescription drug monitoring programs operational characteristics and fatal heroin poisoning",
abstract = "Background: Prescription drug monitoring programs (PDMP), by reducing access to prescribed opioids (POs), may contribute to a policy environment in which some people with opioid dependence are at increased risk for transitioning from POs to heroin/other illegal opioids. This study examines how PDMP adoption and changes in the characteristics of PDMPs over time contribute to changes in fatal heroin poisoning in counties within states from 2002 to 2016. Methods: Latent transition analysis to classify PDMPs into latent classes (Cooperative, Proactive, and Weak) for each state and year, across three intervals (1999–2004, 2005–2009, 2010–2016). We examined the association between probability of PDMP latent class membership and the rate of county-level heroin poisoning death. Results: After adjustment for potential county-level confounders and co-occurring policy changes, adoption of a PDMP was significantly associated with increased heroin poisoning rates (22{\%} increase by third year post-adoption). Findings varied by PDMP type. From 2010–2016, states with Cooperative PDMPs (those more likely to share data with other states, to require more frequent reporting, and include more drug schedules) had 19{\%} higher heroin poisoning rates than states with Weak PDMPs (adjusted rate ratio [ARR] = 1.19; 95{\%} CI = 1.14, 1.25). States with Proactive PDMPs (those more likely to report outlying prescribing and dispensing and provide broader access to law enforcement) had 6{\%} lower heroin poisoning rates than states with No/Weak PDMPs (ARR = 0.94; 95{\%} CI = 0.90, 0.98). Conclusion: There is a consistent, positive association between state PDMP adoption and heroin poisoning mortality. However, this varies by PDMP type, with Proactive PDMPs associated with a small reduction in heroin poisoning deaths. This raises questions about the potential for PDMPs to support efforts to decrease heroin overdose risk, particularly by using proactive alerts to identify patients in need of treatment for opioid use disorder. Future research on mechanisms explaining the reduction in heroin poisonings after enactment of Proactive PDMPs is merited.",
keywords = "Fatal heroin poisonings, Latent classes, Overdose, Prescription drug monitoring programs",
author = "Martins, {Silvia S.} and William Ponicki and Nathan Smith and Ariadne Rivera-Aguirre and Davis, {Corey S.} and Fink, {David S.} and Alvaro Castillo-Carniglia and Henry, {Stephen G.} and Marshall, {Brandon D.L.} and Paul Gruenewald and Magdalena Cerd{\'a}",
year = "2019",
month = "12",
doi = "10.1016/j.drugpo.2019.10.001",
language = "English (US)",
volume = "74",
pages = "174--180",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",

}

TY - JOUR

T1 - Prescription drug monitoring programs operational characteristics and fatal heroin poisoning

AU - Martins, Silvia S.

AU - Ponicki, William

AU - Smith, Nathan

AU - Rivera-Aguirre, Ariadne

AU - Davis, Corey S.

AU - Fink, David S.

AU - Castillo-Carniglia, Alvaro

AU - Henry, Stephen G.

AU - Marshall, Brandon D.L.

AU - Gruenewald, Paul

AU - Cerdá, Magdalena

PY - 2019/12

Y1 - 2019/12

N2 - Background: Prescription drug monitoring programs (PDMP), by reducing access to prescribed opioids (POs), may contribute to a policy environment in which some people with opioid dependence are at increased risk for transitioning from POs to heroin/other illegal opioids. This study examines how PDMP adoption and changes in the characteristics of PDMPs over time contribute to changes in fatal heroin poisoning in counties within states from 2002 to 2016. Methods: Latent transition analysis to classify PDMPs into latent classes (Cooperative, Proactive, and Weak) for each state and year, across three intervals (1999–2004, 2005–2009, 2010–2016). We examined the association between probability of PDMP latent class membership and the rate of county-level heroin poisoning death. Results: After adjustment for potential county-level confounders and co-occurring policy changes, adoption of a PDMP was significantly associated with increased heroin poisoning rates (22% increase by third year post-adoption). Findings varied by PDMP type. From 2010–2016, states with Cooperative PDMPs (those more likely to share data with other states, to require more frequent reporting, and include more drug schedules) had 19% higher heroin poisoning rates than states with Weak PDMPs (adjusted rate ratio [ARR] = 1.19; 95% CI = 1.14, 1.25). States with Proactive PDMPs (those more likely to report outlying prescribing and dispensing and provide broader access to law enforcement) had 6% lower heroin poisoning rates than states with No/Weak PDMPs (ARR = 0.94; 95% CI = 0.90, 0.98). Conclusion: There is a consistent, positive association between state PDMP adoption and heroin poisoning mortality. However, this varies by PDMP type, with Proactive PDMPs associated with a small reduction in heroin poisoning deaths. This raises questions about the potential for PDMPs to support efforts to decrease heroin overdose risk, particularly by using proactive alerts to identify patients in need of treatment for opioid use disorder. Future research on mechanisms explaining the reduction in heroin poisonings after enactment of Proactive PDMPs is merited.

AB - Background: Prescription drug monitoring programs (PDMP), by reducing access to prescribed opioids (POs), may contribute to a policy environment in which some people with opioid dependence are at increased risk for transitioning from POs to heroin/other illegal opioids. This study examines how PDMP adoption and changes in the characteristics of PDMPs over time contribute to changes in fatal heroin poisoning in counties within states from 2002 to 2016. Methods: Latent transition analysis to classify PDMPs into latent classes (Cooperative, Proactive, and Weak) for each state and year, across three intervals (1999–2004, 2005–2009, 2010–2016). We examined the association between probability of PDMP latent class membership and the rate of county-level heroin poisoning death. Results: After adjustment for potential county-level confounders and co-occurring policy changes, adoption of a PDMP was significantly associated with increased heroin poisoning rates (22% increase by third year post-adoption). Findings varied by PDMP type. From 2010–2016, states with Cooperative PDMPs (those more likely to share data with other states, to require more frequent reporting, and include more drug schedules) had 19% higher heroin poisoning rates than states with Weak PDMPs (adjusted rate ratio [ARR] = 1.19; 95% CI = 1.14, 1.25). States with Proactive PDMPs (those more likely to report outlying prescribing and dispensing and provide broader access to law enforcement) had 6% lower heroin poisoning rates than states with No/Weak PDMPs (ARR = 0.94; 95% CI = 0.90, 0.98). Conclusion: There is a consistent, positive association between state PDMP adoption and heroin poisoning mortality. However, this varies by PDMP type, with Proactive PDMPs associated with a small reduction in heroin poisoning deaths. This raises questions about the potential for PDMPs to support efforts to decrease heroin overdose risk, particularly by using proactive alerts to identify patients in need of treatment for opioid use disorder. Future research on mechanisms explaining the reduction in heroin poisonings after enactment of Proactive PDMPs is merited.

KW - Fatal heroin poisonings

KW - Latent classes

KW - Overdose

KW - Prescription drug monitoring programs

UR - http://www.scopus.com/inward/record.url?scp=85073188645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073188645&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2019.10.001

DO - 10.1016/j.drugpo.2019.10.001

M3 - Article

C2 - 31627159

AN - SCOPUS:85073188645

VL - 74

SP - 174

EP - 180

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

ER -